The 9 most recent market catalysts affecting $NRSN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 3, 2026
Corporate Catalyst
Bearish
Impact 60
NeuroSense Therapeutics Updates Health Canada Filing Timeline for PrimeC
NeuroSense Therapeutics announced a revised timeline for its Health Canada New Drug Submission (NDS) for PrimeC, its ALS therapy, moving the target from December 2026 to March 2027…
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 55
NeuroSense to Present Clinical and Biomarker Data at NEALS 2026
NeuroSense Therapeutics (NRSN) announced it will present new clinical and biomarker data for PrimeC, its lead ALS drug candidate, at the NEALS 2026 meeting. This is a routine updat…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 55
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
NeuroSense Therapeutics has filed a U.S. patent application for a novel method of treating traumatic brain injury (TBI) using a combination of ciprofloxacin and celecoxib. This is …
Oct 2, 2026
Corporate Catalyst
Neutral
Impact 75
NeuroSense Therapeutics Receives Nasdaq Noncompliance Notice; Co. Plans To Appeal
NeuroSense Therapeutics (NRSN) has received a Staff Determination from Nasdaq indicating noncompliance with the minimum market value of listed securities (MVLS) requirement of $35 …
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Lander Egaña Gorroño has maintained a 'Buy' rating on NeuroSense Therapeutics (NRSN) and dramatically raised the price target from $8 to $52. This signi…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 65
NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense Therapeutics announced its H1 EPS, showing a substantial reduction in losses compared to the previous year. The EPS improved from $(3.70) to $(2.10), representing a 43.2…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8
HC Wainwright & Co. initiating coverage on NeuroSense Therapeutics with a 'Buy' rating and an $8 price target is a positive development for the company. Analyst coverage, especiall…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
NeuroSense Therapeutics has unveiled a new, three-part development plan for its Amyotrophic Lateral Sclerosis (ALS) drug, PrimeC. This plan replaces a single, large confirmatory tr…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting
NeuroSense Therapeutics (NRSN) is moving forward with a New Drug Submission to Health Canada for its ALS drug, PrimeC, after a constructive pre-NDS meeting. This is a significant s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.